CHIEF FINANCIAL OFFICER · Taysha Gene Therapies, Inc. · Common Stock
Side
A
Value
—
Shares
359.0K
Price
—
Executed
Jan 12, 2026
Disclosed
Jan 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 12 executedJan 14, 2026 disclosed
TSHA · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 30.2% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Alam Kamran filed this Form 4 reporting a grant or award of TSHA on Jan 12, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF FINANCIAL OFFICER
Alam Kamrancik:0001793412
Issuer
Taysha Gene Therapies, Inc.cik:0001806310
Revision history · 0
No field has changed since this record was first ingested.
